Head-to-head · WeighScore
Direct Meds vs MyStart Health
By GLP-1 ScorecardUpdated
Score comparison
Direct Meds has the higher recorded score — 77.6/100 to 61.3/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Direct Meds | MyStart Health |
|---|---|---|
| WeighScore | 77.6/100 | 61.3/100 |
| Grade | C+ | C |
| Site position | #35 | #337 |
| Semaglutide | $249/30 days sublingual · $297/mo injectable | $299/mo (all doses, compounded) |
| Tirzepatide | $299/30 days sublingual · $399/mo injectable | $299/mo (all doses, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #35 · C+
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Strengths
- Injection and sublingual preparations have separately published prices
- Pricing page advertises medication, evaluation, supplies, shipping and nurse access
- Both semaglutide and tirzepatide are listed
- Checked semaglutide campaign states $147 initially, then $297 monthly
What to consider
- Compounded preparations are not FDA-approved products or assumed equivalent across routes
- No-subscription FAQ wording conflicts with the agreement's 30-day recurring charges
- Renewal cancellation requires 48-hour notice; initial-order cancellation has a separate conditional 24-hour window
- Assigned prescribing practice, dispensing pharmacy and selected longer-plan total need confirmation
- Checked campaign excludes Mississippi and Louisiana; confirm state eligibility
Site position #337 · C
FDAWarning letter issued to Matthew Stern, CEO MyStart Health LLC. in September 2025. See the FDA warning-letter database.
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
What to consider
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- FDA issued Matthew Stern, CEO MyStart Health LLC. a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
Direct Meds
Direct Meds scores 77.6/100 (C+). Direct Meds prices compounded injections and sublingual bottles separately; compare the renewal charge and early cancellation cutoff before choosing a plan.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to directmeds.com, Inc. dba DirectMeds in September 2025. See the FDA warning-letter database.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.